DocGo Inc. (DCGO) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 31.3 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While DCGO currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.35) and Max Pain ($0.28) forces dealer call-delta covering toward $1.23.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
DocGo Inc. (DCGO) dropped -2.43% to $0.27, trading at 3% of its 52-week range ($0.24 – $1.17). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Organon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -47.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DCGO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DCGO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, DocGo Inc. (DCGO) ranks #558 by composite RQD confidence (43/100, grade D-) and #815 by equity capitalization ($27.0M). Within this direct 5-issuer industry benchmark cohort, DCGO leads on earnings valuation at N/A trailing P/E, while DCGO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with DCGO at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DCGO
ACTIVE
DocGo Inc. | D- | 43/100 | — | — | -35.0% | -2.43% | $27.0M | Benchmark Subject |
| PIII P3 Health Partners Inc. (Class A) | D- | 38/100 | — | — | -35.0% | +4.22% | $30.5M | /piii-vs-dcgo → |
| BMGL Basel Medical Group Ltd | D+ | 58/100 | — | — | — | +3.26% | $36.0M | /bmgl-vs-dcgo → |
| CCM Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A) | E | 22/100 | — | 5.7% | -35.0% | -4.93% | $15.9M | /ccm-vs-dcgo → |
| EUDA EUDA Health Holdings Limited | D- | 39/100 | — | 43.9% | -35.0% | +1.31% | $46.4M | /euda-vs-dcgo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), DocGo Inc. (DCGO) reported GAAP revenue of $322.2M (-47.7% vs. FY2024 revenue of $616.6M , and -48.4% cumulative change since FY2023) , GAAP net income of -$196.4M, operating cash flow of $34.5M, and free cash flow of $29.9M (-55.0% YoY). On the balance sheet, DCGO closed FY2025 with $217.1M in total assets against $183.8K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $322.2M | -$196.4M | $34.5M | $29.9M | $217.1M | $183.8K |
| FY2024 (FY) | 2024-12-31 | $616.6M | $13.4M | $70.1M | $66.5M | $455.6M | $5.2K |
| FY2023 (FY) | 2023-12-31 | $624.3M | $10.0M | -$64.5M | -$64.5M | — | — |
As of 2026-11-01, DocGo Inc. (NASDAQ: DCGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.27 (-2.43% 1D, market cap $27.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DCGO ranks #558 in composite RQD confidence.
Within the Health Care sector (Medical/Nursing Services), DCGO carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PIII (P3 Health Partners Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $30.5M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, DCGO leads on earnings multiple (N/A) while DCGO leads on capital efficiency (-35.0% ROIC).
Per DCGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822359), DocGo Inc. generated $322.2M in revenue (-47.7% YoY), -$196.4M in net income, and $29.9M in free cash flow against $217.1M in total assets and $183.8K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DCGO last traded at $0.27 (-2.43% on volume of 681,449 shares), positioning the stock -22.86% below its 50-day simple moving average ($0.35) and -52.63% below its 200-day simple moving average ($0.57). Across its 52-week range of $0.24 to $1.17, DCGO sits at the 3.2% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.30).
Why DCGO Stock dropped -2.43% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.